EHAB

Enhabit Inc.

Healthcare · USD

EHAB

Price

$14

+0.21%

Cap

$710M

Earnings

3/4 beat

30d Trend

+0%

EHAB
Loading chart data...
0 data pointsPowered by Brain47
52-week range97%
6.4714.22

Near 52-week highs — limited upside before resistance

Analyst consensus (9 analysts)-1% to target
0 Strong Buy2 Buy6 Hold1 Sell0 Strong Sell

Target range: $13.8$13.8 (consensus: $13.8)

Consensus: Hold

Earnings history

Q4 2025

MET

0.14 vs 0.14

Q3 2025

BEAT

0.17 vs 0.12

Q2 2025

BEAT

0.13 vs 0.1

Q1 2025

BEAT

0.1 vs 0.06

VolatilityLow

Key macro factors

·

Aging Demographic and Healthcare Demand: The growing U.S. aging population and increased Medicare Advantage enrollment are driving higher demand for home-based healthcare services to reduce hospital costs.

·

Labor Shortage in Skilled Nursing: A persistent shortage of skilled nurses in the healthcare sector, particularly in home health, poses challenges for Enhabit in staffing its services, potentially leading to increased labor costs and limiting service expansion.

·

Medicare Reimbursement Rates and Regulatory Changes: The home health and hospice sector is highly sensitive to policy shifts in Medicare reimbursement rates, including proposed cuts, which could directly impact Enhabit's revenue and overall profitability.

Enhabit, Inc. provides home health and hospice services in the United States, operating under Home Health and Hospice segments.

Next earnings:2026-05-06

QUANT SCORE

Building intelligence for this stock. Brain47 needs a few days of price data to calculate technical indicators and generate a full quant score.

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.

Enhabit Inc. (EHAB) — Brain47 AI Score 58/100 | Analysis